Metformin for the Prevention of CRA Recurrence

Jing-yuan Fang, MD, Ph. D414 enrolled

Overview

Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.

Colorectal adenomas are well-known to be precancerous lesions that develop into colorectal cancers on the basis of the adenoma-carcinoma sequence. The effects of screening for colorectal adenomas and removing precancerous lesions on the prevention of colorectal cancer have been established. Because of the high recurrence rates of colorectal adenomas in patients who have undergone polypectomy, the potential chemopreventive agents that may reduce the risk of colorectal adenoma recurrence need to be investigated. Metformin is a widely used diabetes medicine. In recent years, anticancer activity of metformin has been explored. The aim of this study is to investigate the effect of metformin on the recurrence of colorectal adenomas by conducting a randomized, placebo-controlled, prospective clinical.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

414

Conditions

Colorectal Adenoma Metformin Chemoprevention

Interventions

low-dose metforminDRUG

Metformin Pill 250mg/day

high-dose metforminDRUG

Metformin Pill 500mg/day

PlaceboDRUG

Placebo

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Aged 40-80 years without diabetes; 2. CRAs removed without recurrence before recruitment; 3. Must sign the consent form after being fully informed and understanding the purpose and procedure of this study. Exclusion Criteria: 1. Familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome); 2. Regularly taking aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclo-oxygenase 2 (COX2) inhibitors, calcium or vitamin D; 3. Have a history of gastrointestinal surgery; 4. Have severe heart, liver or kidney disease ; 5. Have cancer history; 6. Women with pregnant, during breast-feeding period, or with expect pregnancy; 7. Diabetes（taking diabetes medicines or HbA1c\>6.5%); 8. Inflammatory bowel disease; 9. Mental illness; 10. Intolerant to metformin; 11. Cannot tolerate colonoscopy; 12. Staffs in this clinical trial; 13. Poor bowel preparation for colonoscopy or the examination time is shorter than 6 minutes; 14. Unsuitable for inclusion by the investigator

Locations (1)

Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology & Hepatology, Ministry of Health

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

CRA recurrence rate

Percentage of patients who has recurrence of CRA(colorectal adenoma) during or after chemotherapy with metformin or placebo.

Time frame: one year, two years

Secondary Outcomes

All polypoid lesions incidence rate

Percentage of patients who has incidence of all polypoid lesions during or after chemotherapy with metformin or placebo.

Time frame: one year, two years

CRC incidence rate

Percentage of patients who has incidence of CRC (colorectal cancer) during or after chemotherapy with metformin or placebo.

Time frame: one year, two years

Central Contacts

Jing-Yuan Fang, Professor

CONTACT

+8613918386561 jingyuanfang@sjtu.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.